The Need for Safe Effective Back Pain Relief
Up to 80% of the population in the UK will experience back pain at some stage in their life. During any one year, up to half of the adult population will have back pain and the prevalence of chronic back pain is 23%. In only 15% of patients can a cause be identified. The general aims of treatment are to improve pain and to optimize physical, psychological and social functions. Physical therapies may improve pain and functional status but the vast majority of chronic back pain sufferers resort to drug treatment. Drugs are limited in effectiveness and have serious risks of adverse effects, especially with consistent long-term use. There is a great need for new effective drug free therapies to help people self-manage their back pain and improve their quality of life.
New Development in Back Pain Relief
The ActiPatch® Back Pain product provides advanced long-lasting chronic pain relief using Electromagnetic Pulse Therapy and works great for lower back pain, backaches, arthritis, sciatica, fibromyalgia, strains, sprains and general back pain. ActiPatch® is drug and ingredient-free so is safe for continuous use and can be used while taking any other medication. Unlike a TENS machine, you will not feel heat or vibration. In fact, ActiPatch® is completely sensation free, so the only thing you are going to feel is better.
An ongoing consumer survey of 2,000 UK ActiPatch users, of whom 864 reported back pain as their cause of their pain, emphasises ActiPatch’s benefit for arthritis pain relief. In this survey, the users reported an initial pain score before using ActiPatch of 8.3 where 10 indicates the worst pain and 0 indicates no pain. This high level of average pain clearly indicates that current therapies for the management of arthritis pain are inadequate. After just a 1-week ActiPatch trial, 72% reported an average pain reduction of 4.24 points or 51% in their pain levels; most reported an improvement in the first three days.
About the author
Ian Rawe is the Director of Clinical Research at BioElectronics Corporation, the manufacturer of ActiPatch® Therapy.